A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
A Randomized, Four-arm, Canakinumab Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis
Sponsor: Novartis Pharmaceuticals
Terminated
Sponsor Decision
Other terminated trials from Novartis Pharmaceuticals
Other Knee Osteoarthritis trials with similar outcome
A PHASE2 clinical study on Knee Osteoarthritis, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 33 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
33 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 28 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .